Cyclopharm H1 Revenue Surge Signals Growth in Radiopharmaceutical ETFs

Cyclopharm has officially reported record-breaking revenue figures for the first half of 2026, marking a significant milestone in the company's international expansion strategy. The primary catalyst for this growth is the successful and accelerating…